Clinical Trial Detail

NCT ID NCT03798626
Title Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

renal cell carcinoma

colorectal cancer

gastroesophageal cancer

Therapies

Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052

Paclitaxel + Ramucirumab + XOMA 052

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052

Cabozantinib + XOMA 052

Age Groups: adult senior

No variant requirements are available.